Oria Meds Get started

Semaglutide vs. tirzepatide: how the two differ

Both are weekly prescription injectables for weight management, but they act on different receptors and differ in dosing, side effects and trial results.

By Oria Meds Clinical Team

If you are weighing a prescription weight-management program, these two medication names come up constantly — often as though they were interchangeable. They are not. They act on different receptors, follow different dose schedules, and produced different results in their respective trials.

Here is what actually separates them, and what that means for a conversation with a licensed provider.

The mechanism is the core difference

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone the gut releases after eating. That hormone slows how quickly the stomach empties, signals fullness to the brain, and prompts the pancreas to release insulin when blood glucose rises.

Tirzepatide targets GLP-1 and a second receptor: GIP (glucose-dependent insulinotropic polypeptide). GIP is also an incretin hormone, and the working theory is that engaging both pathways affects appetite and insulin sensitivity more than engaging GLP-1 alone.

That dual action is why tirzepatide is sometimes described as a “dual agonist” while semaglutide is a “single agonist.”

What the trials showed

Both medications were studied in large randomised trials, and both produced clinically meaningful weight reduction compared with placebo when combined with diet and activity changes.

In the STEP trials, participants taking semaglutide 2.4 mg weekly lost substantially more weight than those on placebo over 68 weeks. In the SURMOUNT trials, tirzepatide at its higher doses produced greater average reduction still, over 72 weeks.

A caveat that matters more than the headline numbers: these were separate trials, with different participants, protocols and timeframes. Comparing averages across studies is not the same as a head-to-head comparison. Individual response varies widely — some people respond strongly to one and modestly to the other, and trial averages say nothing about which will suit any particular person.

Dosing and titration

Both are once-weekly subcutaneous injections, and both start low and increase gradually. That ramp is deliberate: it gives the digestive system time to adjust and reduces the intensity of early side effects.

Escalating faster than prescribed does not accelerate results — it mostly intensifies nausea. Dose changes belong with the prescribing provider, not with a schedule found online.

Side effects

The common side effects overlap substantially, and most are gastrointestinal:

  • Nausea
  • Diarrhoea or constipation
  • Vomiting
  • Abdominal discomfort
  • Reduced appetite

These are typically most noticeable in the first weeks and after each dose increase, easing as the body adapts. They are also the most common reason people stop treatment early.

More serious risks — including pancreatitis, gallbladder disease and thyroid C-cell tumours observed in rodent studies — are why both medications require prescription and provider supervision, and why personal and family medical history is part of the eligibility review.

Which one is appropriate?

That is a clinical decision, not a consumer one. A licensed provider weighs medical history, current medications, other conditions, prior treatment response, and tolerance for side effects. Some people are not candidates for either.

What is worth bringing to that conversation:

  • Your full medication list, including supplements
  • Any history of pancreatitis, gallbladder disease or thyroid cancer
  • Family history of medullary thyroid carcinoma or MEN2
  • Previous experience with weight-management medication
  • What you are realistically able to sustain

The part neither medication does on its own

In every trial, the medication was paired with diet and activity changes. Neither was studied as a standalone intervention, and neither behaves as one. They reduce appetite and slow digestion — they do not replace nutrition, movement, sleep or the clinical follow-up that catches problems early.

Programs that treat the injection as the entire intervention are describing something the evidence does not support.

If you want a provider to weigh in

Oria Meds runs both as physician-supervised programs for adults in the United States: compounded semaglutide at $89 for the first month, then $199/month, and compounded tirzepatide at $129 for the first month, then $369/month. Both include the clinical review, the medication, dose adjustments and shipping.

The medical intake is free to complete, and you are charged only if a licensed provider reviews your history and decides treatment is appropriate. If you are not eligible, you pay nothing.

References